Congress funds cancer research with tobacco tariff revenue, prioritizing rare and pediatric cancers.
H.R. 10093 — Cancer Research Trust Fund Act · Filed by Ashley Hinson (R-IA) · Introduced Aug 13, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a dedicated trust fund for cancer research, funded by 10% of federal tariff revenue collected on imported tobacco and tobacco substitute products. The Department of Health and Human Services, in coordination with the Defense Health Agency, would use the money to fund research into cancer screening, prevention, treatments, and therapies, with priority given to rare cancers and pediatric cancers.
Why we flagged it
The bill's operative mechanism is straightforward: it dedicates a revenue stream to a specific public-health research mission. There are no liability shields, carve-outs, or private beneficiaries named. The mechanism is transparent and the purpose is stated plainly.
What the text implies
- The bill does not specify how much total funding will flow to the Fund in any given year, since it depends on tariff collection rates and import volumes, which fluctuate. Actual research capacity may vary significantly year to year.
- The coordination requirement with the Defense Health Agency is unusual for a civilian cancer research program and may signal military medical research applications, though the bill does not elaborate on that role.
The full analysis lists 3 implications of this text.
Who stands to gain
academic medical centers and research institutions; pharmaceutical and biotech companies conducting cancer research; medical device manufacturers developing diagnostic and therapeutic tools